38 / 51
Page 94
Journal of Clinical Immunology and Allergy
ISSN: 2471-304X
E u r o p e a n C o n g r e s s o n
Vaccines & Vaccination
and Gynecologic Oncology
Vaccines & Vaccination and Gynecologic Oncology 2018
O c t o b e r 2 6 - 2 7 , 2 0 1 8
B u d a p e s t , H u n g a r y
A
vaccine is the most cost-effective measure available to protect and promote public health and this principle applies
to use for vaccination of pregnant women. Pregnant women and newborn infants are at increased risk of complications
from certain vaccine-preventable diseases (e.g., influenza, pertussis). The pregnant women in the US are 4-fold greater risk
for hospitalization because of A/H1N1 infection than the general population. Maternal vaccination is an effective approach to
prevent certain infectious diseases because it directly protects the mother and indirectly protects her newborn through passive
antibody transfer. Clinical investigation and definitions for the assessment of outcomes should help expedite a variety of
aspects of vaccine development as well as regulatory decision making. The reduction of child mortality by two- thirds in between
1990-2015 is the millennium development goals. The vaccines Tdap and inactivated influenza are routinely recommended in
the USA by the advisory committee on immunization practices (ACIP) to be administered during each pregnancy. The study
proves the benefits for both mother and babies, it is expected that future maternal immunizations will have to also obtain a
specific indication from the FDA to be administered in this population. In 2014, California experienced a pertussis epidemic with
over 11000 reported cases. Young infants have the highest reported rates of illness, hospitalization and death from pertussis.
Influenza immunization during pregnancy helps protect both mother and baby from influenza and its complications. Changes
to the immune system, heart and lung during pregnancy make pregnant women more susceptible to severe influenza illness,
pneumonia, and hospitalization. Collaboration for evaluation of safety profile recommended vaccines in pregnant women and in
infants born to vaccinated mothers. Very important for success of immunization and safety of vaccines in pregnant women is the
strengthening pharmacovigilence structure. The pharmacovigilence now is almost in every country as part of regulatory agencies
or like center of pharmacovigilence, which is necessary to monitor maternal, fetal and newborn and child health.
emkoni@hotmail.comSafety of vaccines for pregnant women and role
of regulatory system related the issue
Merita Kucuku
National Agency for Medicines and Medical Devices, Romania
Journal of Clinical Immunology and Allergy, Volume: 4
DOI: 10.21767/2471-304X-C2-006
Euro Vaccines 2018